Glenmark Speclt patent expiration
1. Ryaltris patent expiration
RYALTRIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548907 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10016443 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10517880 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9750754 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9078923 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US11400101 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10561672 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9370483 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10376526 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9937189 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10765686 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10758550 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10646500 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US11679210 | GLENMARK SPECLT | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Sep, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and m...
Dosage: SPRAY, METERED
More Information on Dosage
RYALTRIS family patents
